DCAT Value Chain Insights’ Production to Prescription

Hosted by DCAT

Business Science

Website RSS feed LinkedIn

Episodes

Latest episode

Sep 2026

Language

EN-US

About the show

DCAT Value Chain Insights' Production to Prescription podcast, presented by the Drug, Chemical & Associated Technologies Association (DCAT), features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.

Listen to episodes

60 recent

October 1, 202627 min

Biomanufacturing: Capacity Trends & CDMO Insights

What is the state-of-the state for biomanufacturing (drug substance) in terms of industry capacity utilization, in-sourced/outsourced activity, and technology drivers? Is capacity in line with demand or is capacity tightening? How about for the make versus buy decision; is it trending upward or downward for CDMOs of biologics? And how does AI factor into current and future technology needs in bioprocessing, and what else tops the technology interests in both upstream and downstream bioprocessing? In this episode, Eric Langer, Managing Partner & President, BioPlan Associates, Inc., a strategic consulting and business intelligence firm for the biopharmaceutical and life-sciences industries, provides key insights that need to be on your company’s radar. Support the show

September 3, 202617 min

Beyond ADCs: The Market for Next-Generation Conjugates

Next-generation complex conjugates, such as peptide conjugates, radioconjugates, ligand-conjugated antisense medicines, and small-molecule drug conjugates, are expected to outpace growth comparative antibody drug conjugates (ADCs), which are still slated for strong growth. Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market analysis of these next-generation complex conjugates and ADCS. Support the show

August 13, 202631 min

New Excipient Products: Are They Coming?

Support the show

July 9, 202620 min

Pipeline Potential: Small-Molecule Drugs

New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have been several large deals among the bio/pharma majors and smaller innovator companies, with one drug candidate recently gaining FDA approval. What is the market potential and both the promise and limitations of these drug classes? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest insights. Support the show

June 4, 202635 min

CDMO Outlook: Small Molecules—What Lies Ahead?

As the industry reaches the mid-point in 2026, how are CDMOs of small-molecule drugs faring? The larger scale CDMOs with late-phase and/or commercial-scale capabilities are faring well while smaller and mid-sized CDMOs specializing in early-stage development and clinical-scale capabilities are facing some headwinds from more challenging trends in biotech financing, but opportunities lie ahead. Brian Scanlan, Managing Partner, Freedom Bioscience Partners, a strategic advisory firm to CROs, CDMOs, and investors, provides the latest insights. Support the show

May 14, 202623 min

A CDMO Roundtable: The Making of a Molecule: Peptide Synthesis

Support the show

March 5, 202616 min

What Tops the Industry’s Sustainability Agenda for 2026?

As bio/pharma companies and their suppliers set and implement their sustainability strategies, what issues top the industry’s sustainability agenda? Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026. Dr. Ute Schleyer, Vice President, Internal Project Management and EHS Sustainability, Vetter, provides key insights on how bio/pharmaceutical companies and their suppliers are collaborating and the sustainability frameworks supporting these efforts. Support the show

February 5, 202622 min

2026 Outlook: CDMO Market for Injectables

In taking a 360-degree view of the CDMO market for injectables, what are the key developments from 2025 that continue to loom large in 2026? Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and lead of L.E.K.’s Pharmaceutical Contract Services Practice, provided perspectives on evolving US tariff/trade policy, a policy movement in the US to most-favored nation drug pricing, and key technology trends and what impact they may have on the CDMO market for injectabes. Support the show

January 15, 202623 min

2026: Drugs To Watch: The Year Ahead

Which bio/pharmaceuticals, slated to be launched or approved in 2026, may be potential blockbusters or are raising the innovation bar to new heights? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, highlights the 11 drugs making Clarivate’s Drugs to Watch list in 2026, key trends in product innovation, and the companies and products on the industry’s radar. Support the show

December 11, 202537 min

2025: The Bio/Pharma Industry’s Year in Review

Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course of business in the bio/pharmaceutical industry—new drug approvals and the progression of pipelines, including new modalities—was also top of mind. In this special episode of the Production to Prescription podcast , 2025: The Bio/Pharma Industry’s Year in Review, we provide key insights from industry experts and a snapshot of key trends across the bio/pharmaceutical manufacturing value chain that are relevant as the industry moves into 2026. Support the show